ANK-101-004 (ClinicalTrials.gov Identifier: NCT07027514) is a Phase 1 clinical trial evaluating an investigational intratumoral therapy—tolododekin alfa (ANK-101), an anchored interleukin-12 (IL-12) therapy designed for localized immune activation—in adults with advanced or metastatic non-small cell lung cancer. The trial is part of a multicenter research effort.

“OSF HealthCare is steadfast in its commitment to pioneering early-phase oncology research, especially for complex conditions such as advanced non-small cell lung cancer, by partnering with forward-thinking biotechnology innovators to deliver cutting-edge clinical trials to patients,” said Dr. Jun Zhang, Vice President of Oncology Research at OSF HealthCare Cancer Institute. “Engaging in these studies enables us to offer qualified individuals with advanced non-small cell lung cancer the chance for timely access to novel investigational therapies that may help meet critical treatment gaps in this prevalent and often aggressive form of cancer.”

The study includes evaluation of the investigational therapy in combination with an anti-PD-1/PD-L1 antibody, with all treatment approaches being studied for research purposes in accordance with the approved study protocol.

All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673-4467 or email sfmc.clinicaltrials@osfhealthcare.org.